Logo
Ecolla PLLA Dermal Filler 1 x 365mg Vial

Ecolla PLLA Dermal Filler 1 x 365mg Vial

Ecolla

Injectables & Dermal Fillers
  • CE Marked medical device injectable implant based on poly L Lactic acid (PLLA), manufactured under medical device regulatory standards
  • Sterile, absorbable, biocompatible and biodegradable PLLA formulation for soft Tissue augmentation by collagen stimulation
  • Produced by JETEMA Co., Ltd. under documented quality management and device safety systems
  • Distributed in the UK and EU via authorised aesthetic product distributors who state that all products are CE or CPNP approved where appropriate
Poly-L-lactic acid (PLLA) biostimulatory dermal filler

Description

Ecolla PLLA Dermal Filler is a poly-L-lactic acid (PLLA) collagen-stimulating injectable implant supplied as a 365 mg vial of sterile, micronized PLLA powder. Formulated with a biocompatible and biodegradable synthetic polymer, it works as a bio-stimulator: once reconstituted and injected by a suitably trained medical professional, it gradually promotes new collagen formation in the skin. This progressive collagen induction helps restore facial volume, improve skin structure and elasticity, and soften deep lines and wrinkles while maintaining a natural look. Ecolla is indicated for the correction of shallow to deep facial wrinkles and contour deficiencies, including nasolabial folds, marionette lines, sagging jowls and volume loss in areas such as the cheeks and temples. Results are typically first visible from around 4 weeks after treatment and can last for up to approximately 3 years, depending on patient factors and treatment protocol.

Bnefits

  • Stimulates endogenous collagen production for gradual, natural-looking volumisation
  • Improves overall skin structure, firmness and elasticity
  • Softens deep lines and wrinkles while preserving natural facial expression
  • Adds volume and lifts sagging or hollowed areas of the face
  • Suitable for patients from around 30 years of age and above with volume loss or structural ageing
  • Provides long-lasting results, with effects reported for up to approximately 3 years
  • Biocompatible and biodegradable PLLA for gradual resorption over time

Indications

  • Correction of shallow to deep facial wrinkles and folds
  • Nasolabial folds (nose-to-mouth lines)
  • Marionette lines (mouth-to-chin lines)
  • Sagging jowls and jawline contour deficiencies
  • Sunken or hollow cheeks
  • Temporal hollowing
  • Deep dermal contour deficiencies
  • Selected atrophic or volume-related acne and other facial scars (at the clinician’s discretion)
  • General age-related facial volume loss and loss of skin elasticity in appropriately selected patients

Composition

  • Poly-L-lactic acid (PLLA) 365 mg sterile, micronized powder in a single-use vial
  • Formulated as a biocompatible and biodegradable synthetic polymer intended for reconstitution prior to injection

Formulation

  • Sterile lyophilised/micronized poly-L-lactic acid (PLLA) powder
  • Single-use injectable implant for suspension in diluent immediately prior to administration

Packaging

  • Box containing 1 x 365 mg Ecolla PLLA vial
  • Sterile single-use glass vial with rubber stopper and flip-off cap
  • Supplied with product labelling and instructions for use from the manufacturer

Usage

  • For professional use only: Ecolla must be prepared and injected exclusively by appropriately trained and qualified healthcare professionals experienced in PLLA and collagen-stimulating injectables.
  • Reconstitute the 365 mg PLLA powder with the recommended volume of sterile diluent (e.g. normal saline, with or without lidocaine) strictly following the official instructions for use and local guidelines.
  • Allow adequate time after reconstitution for full hydration of the PLLA particles as directed in the manufacturer’s protocol before injection.
  • Inject into the appropriate tissue plane (typically deep dermis or subcutaneous layer) using suitable needles or cannulas and techniques selected by the practitioner according to the treatment area and patient anatomy.
  • Use multiple small aliquots and a fanning or threading technique to achieve even distribution and avoid overcorrection at the time of treatment, as the main effect develops progressively via collagen stimulation.
  • Typical treatment protocols involve a series of sessions spaced several weeks apart (for example, around 4–6 weeks), with the number of vials and sessions tailored to the patient’s degree of volume loss and aesthetic goals.
  • After treatment, follow the manufacturer’s guidance on post-procedure care, which usually includes advising the patient on gentle massage, avoidance of extreme heat or strenuous exercise for a short period, and monitoring for any adverse reactions.
  • Do not inject into blood vessels, into areas of active infection or inflammation, or in patients not medically suitable for PLLA treatment; always consult the full instructions for use before treatment.

Contraindications

  • Known hypersensitivity or allergy to poly-L-lactic acid (PLLA) or any component of the product
  • Presence of active skin infection, inflammation, or dermatitis at or near the intended injection site
  • History of severe allergic reactions or anaphylaxis to injectable implants or similar products
  • Patients with uncontrolled autoimmune or immune-compromising conditions where injectable implants may pose increased risk, according to clinician judgment
  • Known bleeding disorders or current significant anticoagulant therapy that cannot be safely managed for injectable procedures
  • Pregnancy or breastfeeding, due to lack of adequate safety data
  • Use in patients under 18 years of age
  • Any other contraindications outlined in the official Ecolla instructions for use and relevant local regulations

Adverse Effects

  • Transient injection-site reactions such as redness, swelling, pain, tenderness, warmth or bruising
  • Mild to moderate oedema in the treated area shortly after injection
  • Itching or discomfort at the injection site
  • Formation of small palpable papules, nodules or lumps in the treated area, which may be delayed in onset and may require clinical management
  • Asymmetry or irregularity of contour if product distribution is uneven
  • Rare risk of granuloma formation or inflammatory reactions associated with injectable implants
  • Very rare but serious complications such as vascular occlusion or tissue compromise if inadvertently injected intravascularly; emergency management protocols must be in place
  • Any additional adverse events listed in the official manufacturer’s instructions for use

Storage Conditions

  • Store in accordance with the manufacturer’s instructions on the outer packaging and instructions for use.
  • Typically stored at controlled room temperature within the range specified on the label, in a dry place, protected from direct sunlight and excessive heat.
  • Do not freeze unless explicitly permitted by the manufacturer’s guidance.
  • Keep the vial in its original packaging until use to maintain sterility and traceability.
  • Keep out of the reach and sight of children.
  • Do not use after the expiry date printed on the packaging, and discard any unused reconstituted product according to local regulations for medical waste.

Duration

Clinical experience and supplier information indicate that following a full course of treatment, the volumising and collagen-stimulating effects of Ecolla may last for up to approximately 3 years, depending on the patient\u2019s age, skin quality, lifestyle, treatment plan and maintenance.

Onset

Ecolla produces progressive results; early visible improvement is generally observed from around 4 weeks after injection as new collagen forms, with further gradual enhancement over subsequent months following a series of treatments.

Browse more Injectables & Dermal Fillers

Top Treatments

Top Cities in the UK